Compare ABEO & BKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | BKT |
|---|---|---|
| Founded | 1974 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 245.7M |
| IPO Year | 1980 | N/A |
| Metric | ABEO | BKT |
|---|---|---|
| Price | $5.05 | $11.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.20 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 67.9K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.97% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.71 | N/A |
| P/E Ratio | $3.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $10.55 |
| 52 Week High | $7.54 | $12.92 |
| Indicator | ABEO | BKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 48.74 |
| Support Level | $4.37 | $10.85 |
| Resistance Level | $5.17 | $11.17 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 65.80 | 62.87 |
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Blackrock Income Trust Inc is a diversified investment fund with an investment objective to manage a portfolio of high-quality securities to achieve both preservations of capital and high monthly income. The trust seeks to achieve its investment objective by investing at least 65 percent of its assets in mortgage-backed securities. The Fund invests at least 80 percent of its assets in securities that are (i) issued or guaranteed by the U.S. government or one of its agencies or instrumentalities or (ii) rated at the time of investment either AAA by S&P Global Ratings (S&P) or Aaa by Moody's Investors Service, Inc (Moody's). The Fund may invest directly in such securities or synthetically through the use of derivatives.